Philippe Celigny-Solal

Le Mans, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Journal: Leukemia
Published: December 20, 2023

Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.

Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.

Journal: Leukemia & lymphoma
Published: March 01, 2018

A retrospective study on the management of patients with rituximab refractory follicular lymphoma.

A retrospective study on the management of patients with rituximab refractory follicular lymphoma.

Journal: British journal of haematology
Published: June 16, 2017

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.

ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.

Journal: Clinical lymphoma, myeloma & leukemia
Published: February 02, 2017

Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer.

Totally implantable venous access ports: a prospective long-term study of early and late complications in adult patients with cancer.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 25, 2017

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology
Published: January 13, 2017

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.

Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 20, 2016

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.

Journal: Journal of the National Cancer Institute
Published: August 18, 2016

Rituximab by subcutaneous route.

Rituximab by subcutaneous route.

Journal: Expert review of hematology
Published: March 10, 2015

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.

Journal: Blood
Published: June 12, 2014

t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma.

t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 02, 2014

A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.

A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.

Journal: American journal of hematology
Published: March 03, 2014
Showing 1-12 of 20

Last Updated: 09/26/2026